(See KALA stock analysis on TipRanks)Revance Therapeutics (RVNC)Focused on innovative aesthetic and therapeutic offerings, Revance Therapeutics works to address the unmet needs of patients. (To watch Raymond’s track record, click here)Rating wise, Raymond’s colleagues take a similar view. The exploration companies own the rights and bring in the heavy equipment, but it’s the support service providers who send in the roughneck drillers and the tools that complete the wells and keep them in operation. Unsurprisingly, given the lack of EPS growth, the market seems to be more cautious about the stock. The rating might as well have said Sell, as the figure implies there will be a 33% drop from current levels. Weighing in on this, Ju commented, “Its efforts to step up the buildout of its own logistics network to take down the dependency on Correios in Brazil is yielding these tangible results and also places the company to potentially underwrite a greater amount of free shipping subsidies as the unit cost of deliveries continues to decrease... All of this taken together means higher reliability, faster shipping times, and greater cost savings – which can be passed along to the consumer.” Going forward, MELI is expected to invest in Consumer Electronics and CPG categories to fill selection gaps and improve price competitiveness. Hefty upside potential is also on the table here.Kala Pharmaceuticals (KALA)Developing treatments for inflammatory ocular conditions, Kala Pharmaceuticals wants to improve the lives of patients everywhere. Discover the best Children's Day gifts for your kids that they will always be grateful for. (To watch Moussatos’ track record, click here)In general, other analysts echo Moussatos’ sentiment. In the most recent quarter, the company added 9.3 million net registered users, the most ever in a quarter, driven by its increased marketing spend to take advantage of the digital shift brought on by the COVID-19 pandemic. In line with his optimistic approach, Yao stayed with the bulls. But EPS is up 7.2% over the last 3 years. Since the market seems unimpressed with mm2 Asia, it's quite possible it could surprise on the upside. The average price target is $20.27, implying an upside of 58% from the trading price of $12.86. 1.7%. Yet judging from financial markets’ reaction so far, that remains far from traders’ radar.“Our baseline – of a risk-supportive macro outlook despite election uncertainty – will not change unless the president’s health unexpectedly takes a worse turn,” the Barclays strategists wrote.At the same time, there is still no shortage of debate over whether Democratic or Republican policies would be better for investors. In the second quarter, the company recorded a net loss per share of 92 cents. As a result, the 9 cent (US) annualized dividend payment gives a fairly robust yield of 4.8%.Analyst Greg Pardy, of RBC, watches the North American oil industry – especially the Canadian segments – carefully, and he believes Enerplus sits in a strong position to weather a tough market. Instead, his income was paid into accounts held in the names of others, prosecutors claim. So this free report on the analyst consensus forecasts could help you make a master move on this stock. For those who prefer to invest with the flow of momentum, that might be a bad sign, but for deep value investors this stock might justify some research. The mix of Flex and MELI Logistics, which integrates with micro carriers through a software layer, has also been improving. He vowed to "Turn around automotive operations, allocate capital to Ford's strongest franchises and high-growth opportunities; produce compelling uniquely Ford electric vehicles at scale; and stand up new AV-enabled businesses. Moreover, DAXI had demonstrated a peak treatment effect of 50% in its earlier Phase 2 trial, which, in our view, is best-in-class,” Fernandez explained. Investors could be pocketing a gain of 95%, should this target be met in the twelve months ahead. ACN 600 056 611, Simply Wall St is a financial technology startup focused on providing unbiased, high-quality research coverage on every listed company in the world.